CEO/CSO

Dr. Mahan was appointed in April 2018 as lead executive responsible for running the company’s operations, leading equity financings and business development activities. With the passing of Dr. Poulter, Dr. Mahan now additionally serves as Chief Scientific Officer guiding the company’s epilepsy focused programs. Prior to joining OB Pharmaceuticals, Dr. Mahan has served as Chief Scientific Officer of Madeleine Pharmaceuticals, Inc. leading IND enabling R&D and CMC programs together with regulatory and clinical strategy for a cardiorenal biotherapeutic for heart failure. As president of BioConsult USA he provided professional consulting services in the innovation management of advanced biomedical technologies; having acted within and outside organizations to accelerate their mission and strategic vision. His specialties include technology evaluation, venture diligence, entrepreneur guidance and business strategy creation with a domestic and international track record in business alliance development.

His business expertise builds upon more than 20 years as an accomplished senior scientist in biomedical research including 12 years at the National Institutes of Neurological Disorders and Stroke (NINDS) and Mental Health (NIMH). His research has encompassed cellular and molecular biology, pharmacology, functional genomics and proteomics and genetic engineering in the neurosciences and immunology with additional experience in biomedical device engineering principals and bioinformatics.

Dr. Mahan past roles have included Director of Innovation and Business Development for Children’s National Medical Center, Executive Director of the Maryland Biotechnology Center, Director of Biosciences & Advanced Technologies for the Maryland Department of Commerce, Senior Strategy Advisor to the Office of the Governor and co-founder of TherExcell, Inc. Dr. Mahan holds a doctorate in Physiology and Pharmacology from the University of California, San Diego with more than 100 published articles and abstracts and holds four U.S. patents. He has been an invited speaker globally on his scientific research and industry development in the biosciences.